BlueCrest Capital Management’s Immunic IMUX Stock Holding History

BlueCrest Capital Management’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-81	Closed	-$219K	–	1654
2018 Q1	$219K	Sell	81 -2	-2%	-$4.59K	0.01%	1242
2017 Q4	$197K	Buy	+83	New	+$183K	0.01%	718
2017 Q3	–	Sell	-54	Closed	-$63K	–	968
2017 Q2	$63K	Buy	+54	New	+$72.1K	﹤0.01%	847

Other funds holding IMUX

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlueCrest Capital Management's IMUX Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Immunic (IMUX) in Q2 2018, closing a stake of 81 shares — an estimated $219K sold.

BlueCrest Capital Management first reported a position in IMUX in Q2 2017 and held it in 3 quarters. The position peaked at $219K in Q1 2018. 62 funds tracked by Wall St. Rank hold IMUX as of Q2 2018.

BlueCrest Capital Management reported no remaining Immunic position as of Q2 2018 after selling out during the quarter.
BlueCrest Capital Management sold 81 Immunic shares in Q2 2018, an estimated $219K.
BlueCrest Capital Management first reported a position in Immunic in Q2 2017 and held it in 3 quarters.
BlueCrest Capital Management's Immunic position peaked at $219K in Q1 2018.
62 funds tracked by Wall St. Rank held Immunic as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.